Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.

Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.

Management presented a strategy for establishing new blockbuster brands in migraine, RSV, inflammatory bowel disease, cancer and diabetes/obesity during an investor day.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.